Visit us at booth 821 at the ASGCT Annual Meeting. We help you analyze more data in more depth, so you can produce more effective therapies. Attending the ASGCT Annual Meeting? Schedule a meeting with our team to discuss our: AI-powered digital pathology solutions...
Visit Us at Booth 2866 in the West Building, Level 2 Flagship Biosciences is your source for spatial biology expertise, moving your research forward every step of the way. Our mission is to explore complex biomarkers within the context of disease in order to advance...
Reuniting 100+ leading experts in biotech, pharma, and academia. February 21-23, 2023. We’re headed to Boston to join other leading experts in biotech, pharma and academia to discuss obstacles in clinical trials and strategies for delivering safer and more effective...
Join Flagship for the Oncology Companion Diagnostics Xchange at hubXchange West. February 6-9, 2023. Attending hubXchange West? Meet with us to discuss how we can partner with you for end-to-end support of your immunotherapy research and development program....
Visit Flagship at the SB-IO Summit.January 17-19, 2023. Attending the inaugural SB-IO Summit? Stop by our booth to discuss how we can partner with you for end-to-end support of your immunotherapy research and development program. AI-powered digital pathology solutions...
Visit Flagship at ASH | Booth #1015. December 10-13, 2022. Attending ASH 2022? Stop by our booth to discuss how we can partner with you for end-to-end biomarker support. Discover our recently expanded services menu and pick up a map of our favorite New Orleans...
Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.
NEWS
Genomenon’s genomic landscapes enhance Flagship’s biomarker services and companion diagnostic development solutionsBroomfield, CO and Ann Arbor, MI – February 7, 2023 – Flagship Biosciences, a leader in spatial biology and biomarker analytics services, today announced...
Accomplished industry executive strengthens company’s position as a leader in spatial biology and biomarker analytics.BROOMFIELD, CO - September 27, 2022 — Flagship Biosciences, Inc., a leader in spatial biology and biomarker analytics services, announced the hiring...
Acquisition significantly expands Flagship’s portfolio of biomarker and analytics servicesBroomfield, CO – August 31, 2022 — Flagship Biosciences, Inc., a leader in spatial biology and biomarker analytics services, announced the acquisition of Interpace Pharma...
PUBLICATIONS/POSTERS
In partnership with Leap Therapeutics (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, Flagship Biosciences published this downloadable original research article. It was first published on Monday, May 10...
Background Dickkopf-1 (DKK1) is a secreted modulator of Wnt signaling that is frequently overexpressed in tumors and associated with a poor prognosis. In this study, we demonstrate an approach for clinically validating a RNAscope chromogenic in-situ hybridization...
Background The Dako PD-L1 (22C3) antibody is used to measure tumor PD-L1 levels in non-small cell lung cancer (NSCLC), serving as a companion diagnostic to the check point inhibitor drug pembrolizumab. However, interpretation of the PD-L1 (22C3) immunohistochemistry...